Start Date
November 30, 2023
Primary Completion Date
November 30, 2028
Study Completion Date
April 30, 2029
oral azacitidine (CC-486)
Oral azacitidine is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
Yale Comprehensive Cancer Center, New Haven
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
National Cancer Institute (NCI)
NIH
Yale University
OTHER